Structured Lipids sn-2 Palmitic Acid Infant Formula
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Infant formulas containing conventional triglycerides lead to increased fat mass accumulation and obesity later in life, as they result in reduced bioavailability of calcium and harder stools, whereas structured triglycerides with palmitic acid residues in the sn-2 position may offer a healthier lipid profile.
Innovation Solution
Administering infant formulas or growing-up milks with triglycerides comprising at least 10 wt.% palmitic acid residues, with at least 30 wt.% of these residues in the sn-2 position, to promote lean body mass, reduce fat mass relative to total body weight, and decrease fat accumulation and visceral obesity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional triglycerides with palmitic acid in sn-1 and sn-3 positions are used in infant formula, then the lipid component is easy to manufacture, but calcium bioavailability is reduced and stool hardness increases
Solution Approach 1:
The patent applies parameter changes by modifying the positional distribution of palmitic acid residues in triglycerides from the conventional sn-1/sn-3 configuration to a structured configuration with palmitic acid primarily in the sn-2 position. This structural parameter change resolves the contradiction by improving calcium bioavailability and stool consistency while maintaining manufacturability through enzymatic interesterification processes.
Solution Approach 2:
The patent creates a composite lipid structure by combining specific fatty acid residues in defined positions within the triglyceride molecule. The structured triglyceride comprises palmitic acid residues (at least 30% in sn-2 position) combined with other fatty acids in specific ratios, creating a composite material that simultaneously achieves good manufacturability and improved calcium absorption.
2Device complexity
If conventional triglycerides are used in infant formula, then the formulation is simple, but fat mass accumulation increases later in life
Solution Approach 1:
The patent changes the structural parameters of triglycerides by repositioning palmitic acid residues to the sn-2 position through enzymatic interesterification. This parameter change in lipid structure programs metabolic pathways during infancy that prevent excessive fat mass accumulation later in life, while keeping the formulation relatively simple.
Solution Approach 2:
The patent applies preliminary action by providing structured triglycerides during the critical early life period (infancy). This early nutritional intervention programs metabolic imprinting that has long-term effects on fat mass regulation, preventing obesity later in life before the individual is exposed to other dietary factors.
3Reliability
If structured triglycerides with palmitic acid in sn-2 position are used, then calcium absorption and bone mass increase, but the lipid structure becomes more complex
Solution Approach 1:
The patent optimizes the parameter of palmitic acid positioning by achieving at least 30% (preferably at least 40%) of palmitic acid residues in the sn-2 position through controlled enzymatic interesterification. This specific parameter range achieves optimal calcium absorption and bone mass benefits while managing structural complexity.
Solution Approach 2:
The patent uses specific enzymes (lipases or interesterification enzymes) as intermediaries to achieve the desired triglyceride structure. These enzymes mediate the rearrangement of fatty acid residues to create the structured triglyceride configuration that improves calcium absorption, bridging the gap between simple原料 and complex functional structure.
4Quantity of substance
If vegetable oils with palmitic acid in sn-1 and sn-3 positions are used, then the oil is readily available and inexpensive, but pancreatic lipases hydrolyse palmitic acid forming calcium-fatty acid complexes that reduce calcium bioavailability
Solution Approach 1:
The patent fundamentally changes the positional parameter of palmitic acid in triglycerides from sn-1/sn-3 to sn-2 position through enzymatic interesterification. This parameter change prevents pancreatic lipases from releasing free palmitic acid that would form calcium-fatty acid complexes, thereby maintaining calcium bioavailability while using readily available vegetable oil sources.
Solution Approach 2:
The patent converts the potentially harmful effect of pancreatic lipase activity into a benefit. By pre-structuring the triglycerides with palmitic acid in the sn-2 position, the natural lipase action is redirected to release less harmful fatty acids, while the protected sn-2 palmitic acid is absorbed directly without forming calcium complexes, turning a metabolic pathway that causes harm into one that provides benefit.
Data Source
AI summary
The invention relates to the use of triglycerides which an enhanced portion of the palmitic acid residues in the sn-2 position for an early in life diet for improving the development of a healthy body composition, in particular prevention of obesity, later in life.